Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Non Operating Income: 2009-2025

Historic Non Operating Income for Amicus Therapeutics (FOLD) over the last 14 years, with Sep 2025 value amounting to $10.9 million.

  • Amicus Therapeutics' Non Operating Income rose 433.65% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year increase of 200.89%. This contributed to the annual value of -$9.4 million for FY2024, which is 40.57% up from last year.
  • Latest data reveals that Amicus Therapeutics reported Non Operating Income of $10.9 million as of Q3 2025, which was up 972.61% from $1.0 million recorded in Q2 2025.
  • Amicus Therapeutics' Non Operating Income's 5-year high stood at $13.6 million during Q3 2022, with a 5-year trough of -$18.6 million in Q4 2022.
  • Over the past 3 years, Amicus Therapeutics' median Non Operating Income value was -$2.9 million (recorded in 2023), while the average stood at -$1.2 million.
  • Within the past 5 years, the most significant YoY rise in Amicus Therapeutics' Non Operating Income was 5,652.74% (2022), while the steepest drop was 10,730.23% (2022).
  • Amicus Therapeutics' Non Operating Income (Quarterly) stood at -$172,000 in 2021, then slumped by 10,730.23% to -$18.6 million in 2022, then soared by 84.54% to -$2.9 million in 2023, then soared by 187.01% to $2.5 million in 2024, then surged by 433.65% to $10.9 million in 2025.
  • Its Non Operating Income stands at $10.9 million for Q3 2025, versus $1.0 million for Q2 2025 and $550,000 for Q1 2025.